<DOC>
	<DOCNO>NCT02480387</DOCNO>
	<brief_summary>Target Population : Hepatitis C Treatment Naïve , non-cirrhotic , Chronic genotype 1 hepatitis C virus ( HCV ) infect adults co-infected human immunodeficiency virus ( HIV ) -1and HCV RNA &lt; 6 x106 IU/mL Duration Subjects treat 8 week follow 24 week post- Treatment : treatment</brief_summary>
	<brief_title>Efficacy Safety Ledipasvir/Sofosbuvir Fixed-Dose Combination 8 Weeks Subjects With Chronic Genotype 1 HCV HIV-1 Co-infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir , sofosbuvir drug combination</mesh_term>
	<criteria>Chronic HCV GT1 , treatmentnaïve , noncirrhotic adult subject . HCV RNA level 10,000 IU/mL less 6,000,000 IU/mL Screening Gastrointestinal disorder postoperative condition could interfere absorption study drug . Solid organ transplantation . Significant cardiac disease significant comorbidities could interfere study treatment . Malignancy within 3 year prior screen , exception specific cancer cure surgical resection ( basal cell skin cancer , etc. ) . Subjects evaluation possible malignancy eligible . Infection hepatitis B virus ( HBV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>